The National Association of Chain Drug Stores has urged the House of Representatives to improve Medicare Part D and control prescription drug spending in health care reform legislation.


NACDS, National Association of Chain Drug Stores, health care reform, House of Representatives, Medicare Part D, prescription drug spending, health care reform legislation, Medicaid reform, durable medical equipment, pharmacy, average manufacturer price, AMP, AMP multiplier, Steve Anderson, Geoff Walden
































































































































































































































INSIDE THIS ISSUE
News
Opinion
Other Services
Reprints / E-Prints
Submit News
White Papers

Inside This Issue - News

Legislation is critiqued by NACDS

August 3rd, 2009

ALEXANDRIA, Va. – The National Association of Chain Drug Stores has urged the House of Representatives to improve Medicare Part D and control prescription drug spending in health care reform legislation.

In letters to House committee leaders the association urged that pro-patient and pro-pharmacy measures — including Medicaid reform, access to durable medical equipment supplies and services, and a heightened role for pharmacy — be part of a revamped system.

NACDS commended Congress for a proposal to extend Part D discounts for branded drugs in the coverage gap.

But “additional clarity can be provided in the language to ensure that pharmacies would not be expected to cover the discounted portion of a covered drug’s price until the plan has received payment from the manufacturer,” NACDS president and chief executive officer Steve Anderson said in one letter to lawmakers.

The letter also called for more extended days’ supplies of Part D medications for chronic conditions; eliminating a requirement to obtain signed, written requests from beneficiaries; and establishment of a rolling enrollment period.

Another letter from Anderson, addressed to three House committee chairmen, calls for additional changes to the average manufacturer price (AMP) definition for Medicaid pharmacy reimbursements.

“For example, sales of certain drugs to hospitals, physicians and clinics remain part of the AMP definition,” Anderson wrote. “Clearly, these entities are not part of the retail class of trade, and inclusion of these sales skews the AMP benchmark downward.”

He also expressed concern about a proposed 130% AMP multiplier. “This multiplier will result in insufficient reimbursement to pharmacies for dispensing generic drugs,” Anderson said.

MORE ON HEALTH CARE REFORM:

House moves closer to deal on health care

Hard bargaining on health care reform under way

NACDS is heard in legislative fray

Wal-Mart backs employer insurance mandate

RxImpact Day hits Washington

Pharmacy advocates tout MTM’s potential

Health care reform debate gets serious

 

Advertisement